CIM
DXCM icon

Contravisory Investment Management’s DexCom DXCM Stock Holding History

Contravisory Investment Management’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-800
Closed -$19K – 307
2018
Q2 		$19K Hold
800
– – 0.01% 235
2018
Q1 		$15K Hold
800
– – 0.01% 247
2017
Q4 		$11K Hold
800
– – ﹤0.01% 266
2017
Q3 		$10K Buy
+800
New +$14.1K ﹤0.01% 275

Other funds holding DXCM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Contravisory Investment Management's DXCM Position: Q3 2018 in Review

Contravisory Investment Management sold out of DexCom (DXCM) in Q3 2018, closing a stake of 800 shares — an estimated $19K sold.

Contravisory Investment Management first reported a position in DXCM in Q3 2017 and held it in 4 quarters. The position peaked at $19K in Q2 2018. 363 funds tracked by Wall St. Rank hold DXCM as of Q3 2018.

  • Contravisory Investment Management reported no remaining DexCom position as of Q3 2018 after selling out during the quarter.
  • Contravisory Investment Management sold 800 DexCom shares in Q3 2018, an estimated $19K.
  • Contravisory Investment Management first reported a position in DexCom in Q3 2017 and held it in 4 quarters.
  • Contravisory Investment Management's DexCom position peaked at $19K in Q2 2018.
  • 363 funds tracked by Wall St. Rank held DexCom as of Q3 2018.

Based on Contravisory Investment Management's 13F filing for Q3 2018, filed 11 Oct 2018.